Clinical Trials
2 trialsNCT05495828 2023-10-26
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Peking University People's Hospital
Unknown
NCT05014100 2021-08-27
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma
Puyang Oilfield General Hospital
Phase 2 Unknown